✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthAnxietyResearchSafety Why This Matters This finding is clinically significant because it challenges the common...
Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The Hill
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyTHC Why This Matters Cannabis hyperemesis syndrome represents an emerging clinical entity with increasing ED...
New York Cannabis, Five Years In: Markets, Medicine, and the Messy Middle
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchCBDTHCIndustry Why This Matters Clinicians in New York need to understand the fragmented cannabis landscape...
Cannabis Hyperemesis Syndrome: Clinical Signs to Watch
✦ New CED Clinical Relevance#78Strong Clinical RelevanceHigh-quality evidence with meaningful patient or clinical significance. ResearchSafetyTHCNeurology Why This MattersCannabis hyperemesis syndrome represents an increasingly prevalent clinical entity that clinicians must recognize, as the...
Daily Digest: Last 48 Hours: CHS, Prenatal Risk, and the Limits of THC Blood Testing — March 01, 2026
A synthesis of 40 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – KGET.com
WHY IT MATTERS: If you use cannabis daily or near-daily and experience recurring vomiting episodes that seem to improve with hot showers, discussing CHS with your doctor is important because the only reliable treatment is stopping cannabis use entirely. CLINICAL OVERVIEW: Cannabis hyperemesis syndrome (CHS) is a paradoxical condition in which chronic, heavy cannabis users develop cyclical episodes of severe nausea, vomiting, and abdominal pain, despite cannabis being widely recognized for its antiemetic properties. The syndrome is strongly associated with long-term, high-frequency use, particularly of high-potency THC products, and a hallmark feature is temporary relief of symptoms through hot showers or baths.
As Congress debates hemp-derived THC ban, Pa. lawmakers look for other options
WHY IT MATTERS: If Pennsylvania moves hemp THC drinks into beer distribution channels, patients and recreational consumers should know these products carry real psychoactive effects and require the same careful dosing consideration as any other THC product. CLINICAL OVERVIEW: Hemp-derived THC beverages occupy a regulatory gray zone created by the 2018 Farm Bill, which legalized hemp but left intoxicating hemp products in an undefined space between federal cannabis law and state alcohol regulation. Pennsylvania lawmakers are now exploring frameworks that would treat these drinks similarly to alcohol, potentially routing them through licensed beer distributors as a way to establish age verification, purchase limits, and product standards.
420 with CNW – Texas Grapples with Increasing Cases of Marijuana DUI
WHY IT MATTERS: If Texas moves toward a per se THC limit for driving, patients using cannabis for legitimate medical purposes could face DUI charges even when they are not functionally impaired, because THC and its metabolites can persist in blood well beyond any period of active intoxication. CLINICAL OVERVIEW: Cannabis-impaired driving remains a serious public safety challenge because THC affects psychomotor function, reaction time, and divided attention in ways that meaningfully increase crash risk. Unlike alcohol, there is no validated per se blood THC threshold that reliably correlates with functional impairment, making enforcement both scientifically and legally complicated.
Hemp article tells us why WI needs government regulations | Letter – Milwaukee Journal Sentinel
WHY IT MATTERS: If you are buying hemp-derived CBD or delta-8 products at a gas station or retail store in Wisconsin, there is currently no reliable guarantee that what is on the label matches what is in the product, including the THC content. CLINICAL OVERVIEW: Hemp-derived products sold legally in retail settings are not subject to the same testing and labeling requirements as products sold through licensed cannabis dispensaries, creating a significant gap in consumer protection. When products contain more THC than disclosed or permitted, consumers have no reliable way to know what they are actually ingesting, which raises meaningful concerns about unintended intoxication, drug interactions, and impaired driving.
In the Mix: 8 More Articles — February 28, 2026
8 cannabis articles reviewed and scored below the CED clinical relevance threshold in the February 28, 2026 feed update. Organized by topic with summaries and source links.